Skip to main content
Premium Trial:

Request an Annual Quote

Regeneron Appoints Bioinformatics VP and New Chief Scientist

Premium

TARRYTOWN, NY--Regeneron Pharmaceuticals here has named David Valenzuela to the position of vice-president of genomics and bioinformatics. He was previously Regeneron's senior director for genomics and bioinformatics. In addition, the company added the title of chief scientific officer to the position of George Yancopoulos, who remains the company's senior vice-president of research.

Commenting on Valenzuela's promotion, Yancopoulos noted that the bioinformatics executive "is responsible for the identification and cloning of novel genes that serve as targets for drug screens." Yancopoulos continued, "David has made many key discoveries for Regeneron in the last four years, and we believe that in his new position David will continue to make important contributions to the company's drug discovery
programs."

Regeneron focuses on applying molecular and cell biology to the task of drug discovery.

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.